StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Nektar Therapeutics's total assets was $1.10B at Jun 30, 2026. For fiscal 2025 it was $280.41M, down 7.7% from the year before. Over ten years it grew -5.6% a year on average. The highest annual figure on record is $2.15B in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$280.41M-7.7%
FY2024Dec 31, 2024$303.85M-23.7%
FY2023Dec 31, 2023$398.03M-44.0%
FY2022Dec 31, 2022$710.60M-36.4%
FY2021Dec 31, 2021$1.12B-27.4%
FY2020Dec 31, 2020$1.54B-22.2%
FY2019Dec 31, 2019$1.98B-8.0%
FY2018Dec 31, 2018$2.15B+322.5%
FY2017Dec 31, 2017$508.87M-10.5%
FY2016Dec 31, 2016$568.87M+14.1%
FY2015Dec 31, 2015$498.64M+12.9%
FY2014Dec 31, 2014$441.62M+1.6%
FY2013Dec 31, 2013$434.53M-12.7%
FY2012Dec 31, 2012$497.79M-17.9%
FY2011Dec 31, 2011$606.55M+16.4%
FY2010Dec 31, 2010$521.23M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.10B+327.4%
Q4 FY2025Dec 31, 2025$280.41M-7.7%
Q3 FY2025Sep 30, 2025$301.35M-2.1%
Q2 FY2025Jun 30, 2025$207.53M-39.6%
Q1 FY2025Mar 31, 2025$256.24M-35.3%
Q4 FY2024Dec 31, 2024$303.85M-23.7%
Q3 FY2024Sep 30, 2024$307.97M-30.4%
Q2 FY2024Jun 30, 2024$343.33M-30.5%
Q1 FY2024Mar 31, 2024$396.01M-29.5%
Q4 FY2023Dec 31, 2023$398.03M-44.0%
Q3 FY2023Sep 30, 2023$442.24M-43.4%
Q2 FY2023Jun 30, 2023$494.28M-42.7%
Q1 FY2023Mar 31, 2023$561.74M-45.1%
Q4 FY2022Dec 31, 2022$710.60M-36.4%
Q3 FY2022Sep 30, 2022$781.01M-38.9%
Q2 FY2022Jun 30, 2022$861.99M-37.1%
Q1 FY2022Mar 31, 2022$1.02B-29.7%
Q4 FY2021Dec 31, 2021$1.12B-27.4%
Q3 FY2021Sep 30, 2021$1.28B-15.3%
Q2 FY2021Jun 30, 2021$1.37B-14.0%
Q1 FY2021Mar 31, 2021$1.46B-22.8%
Q4 FY2020Dec 31, 2020$1.54B-22.2%
Q3 FY2020Sep 30, 2020$1.51B-27.8%
Q2 FY2020Jun 30, 2020$1.59B-24.0%
Q1 FY2020Mar 31, 2020$1.89B-12.9%
Q4 FY2019Dec 31, 2019$1.98B-8.0%
Q3 FY2019Sep 30, 2019$2.09B-7.1%
Q2 FY2019Jun 30, 2019$2.10B-9.2%
Q1 FY2019Mar 31, 2019$2.17B+336.1%
Q4 FY2018Dec 31, 2018$2.15B+322.5%
Q3 FY2018Sep 30, 2018$2.25B+286.4%
Q2 FY2018Jun 30, 2018$2.31B+386.1%
Q1 FY2018Mar 31, 2018$496.79M-6.0%
Q4 FY2017Dec 31, 2017$508.87M-10.5%
Q3 FY2017Sep 30, 2017$582.06M+36.9%
Q2 FY2017Jun 30, 2017$475.86M+2.8%
Q1 FY2017Mar 31, 2017$528.49M–
Q4 FY2016Dec 31, 2016$568.87M–
Q3 FY2016Sep 30, 2016$425.10M–
Q2 FY2016Jun 30, 2016$463.10M–

More Nektar Therapeutics figures

See a number that looks wrong?